208 related articles for article (PubMed ID: 29546589)
1. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.
Tängdén T; Cojutti PG; Roberts JA; Pea F
Clin Pharmacokinet; 2018 Nov; 57(11):1399-1405. PubMed ID: 29546589
[TBL] [Abstract][Full Text] [Related]
2. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
5. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients.
Zhao W; Baudouin V; Zhang D; Deschênes G; Le Guellec C; Jacqz-Aigrain E
Clin Pharmacokinet; 2009; 48(5):321-8. PubMed ID: 19566115
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment Failure.
Jorga K; Reigner B; Chavanne C; Alvaro G; Frey N
CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):167-176. PubMed ID: 30354026
[TBL] [Abstract][Full Text] [Related]
9. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
Welker H; Farhan M; Humar A; Washington C
Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Selby PR; Heffernan AJ; Yeung D; Warner MS; Peake SL; Hahn U; Wallis SC; Mcwhinney B; Ungerer JPJ; Shakib S; Roberts JA
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0155022. PubMed ID: 36815858
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration.
Chen B; Hu SS; Rui WB; An HM; Zhai XH; Wang XH; Lu JQ; Shao K; Zhou PJ
J Clin Pharmacol; 2021 Mar; 61(3):328-338. PubMed ID: 32926418
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
16. Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children.
Facchin A; Benyoub N; Elie V; Magreault S; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0159722. PubMed ID: 36880779
[TBL] [Abstract][Full Text] [Related]
17. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
18. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.
Åsberg A; Bjerre A; Neely M
Pediatr Transplant; 2014 Feb; 18(1):103-11. PubMed ID: 24152053
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.
Pappo A; Peled O; Berkovitch M; Bilavsky E; Rom E; Amir J; Krause I; Yarden-Bilavsky H; Scheuerman O; Ashkenazi-Hoffnung L
Transplantation; 2019 Aug; 103(8):1730-1735. PubMed ID: 31343571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]